Saxenda Manufacturer Copay Program: How to Cut Your Out-of-Pocket Cost in 2026

What Is the Saxenda Manufacturer Copay Program?

Novo Nordisk offers a copay assistance card called the Saxenda My$avings Card to help commercially insured U.S. Patients reduce their monthly out-of-pocket cost. Eligible patients may pay as little as $25 per month, with the manufacturer covering a portion of the remaining balance up to a defined annual cap. The card is available for up to 24 months per enrollment period, after which patients must re-evaluate options.

How the My$avings Card Works

When a pharmacist runs the card as a secondary payment method, Novo Nordisk's third-party processor pays the difference between your copay and the program's maximum benefit. The exact maximum benefit changes annually. As of early 2026, the card offset covers costs above the $25 patient share, subject to an annual dollar limit that Novo Nordisk publishes on the program website.

Patients activate the card online or by phone, receive a card number immediately, and present it at any participating retail or mail-order pharmacy. No paper forms are required at activation. The card does not change your insurance billing; it acts as a secondary payer at point of sale.

Who Is Eligible

To qualify, patients must:

• Have commercial (private) insurance that covers Saxenda
• Be a U.S. Resident
• Not be enrolled in a federal or state government insurance program (Medicare, Medicaid, TRICARE, CHIP, or VA benefits)
• Meet any income criteria Novo Nordisk sets for the current program year

Income thresholds and maximum benefit amounts are updated periodically. The FDA's Office of Prescription Drug Promotion has guidance on manufacturer assistance programs and their disclosure requirements, which can help you understand what questions to ask before enrolling. [1]

What the Card Does Not Cover

The My$avings Card cannot be used when Saxenda is not covered by your commercial plan, when you are uninsured, or when you are on a government plan. In those situations, separate programs (detailed below) apply.

Saxenda's Real Cash-Pay Cost and Why It Matters

Without insurance or a copay card, Saxenda costs approximately $1,349 per month at U.S. Retail pharmacies. That figure reflects a 5-pen carton (each pen containing 18 mg/3 mL of liraglutide) and represents the average nationwide retail price as of late 2025. Prices vary by pharmacy chain and geographic market.

Why the List Price Is So High

Liraglutide 3 mg holds no generic competition in the United States as of 2026. The FDA approved Saxenda in December 2014, and Novo Nordisk's patent protection remains active, which keeps the drug in the branded-only market. The FDA's drug approval database confirms the December 23, 2014, NDA approval for liraglutide 3 mg. [2]

Obesity pharmacotherapy, broadly, remains inconsistently covered by insurance. A 2023 analysis published in JAMA found that only 42% of large employer health plans included any GLP-1 agonist approved for weight management on their formulary, leaving a substantial portion of patients exposed to full list prices. [3]

Comparing Saxenda to Compounded Liraglutide

Compounded liraglutide has appeared at prices ranging from $150 to $400 per month from 503A and 503B compounding pharmacies. The FDA has, however, raised concerns about the safety and quality of compounded versions of GLP-1 medications. The FDA's guidance on compounded GLP-1 drugs notes that compounded drugs lack the agency's pre-market approval for safety and efficacy. [4] HealthRX providers do not prescribe compounded liraglutide without documented clinical justification.

How Saxenda Insurance Coverage Works

Getting insurance to cover Saxenda requires meeting the plan's medical necessity criteria, which usually mirror FDA labeling. Coverage rates have improved since 2020 but remain inconsistent across plan types.

FDA-Labeled Indications

The FDA approved Saxenda for:

• Adults with a BMI of 30 kg/m² or greater (obesity)
• Adults with a BMI of 27 kg/m² or greater (overweight) plus at least one weight-related comorbidity (type 2 diabetes, hypertension, or dyslipidemia)
• Adolescents aged 12 to 17 with a body weight above 60 kg and an initial BMI at or above the 95th percentile for age and sex [2]

The FDA label for liraglutide 3 mg specifies that treatment should be discontinued after 16 weeks if the patient has not lost at least 4% of baseline body weight, because continued treatment is unlikely to achieve meaningful clinical benefit. [5]

Commercial Insurance Prior Authorization

Most commercial plans require a prior authorization (PA) for Saxenda. Standard PA documentation includes:

1. BMI measurement with date
2. Documentation of comorbidity (if BMI is 27 to 29.9)
3. Evidence of a structured diet and exercise program attempted for at least 3 to 6 months
4. Prescriber attestation that the patient does not have a contraindication (personal or family history of medullary thyroid carcinoma or MEN2)

The American Association of Clinical Endocrinology's 2023 obesity guidelines recommend initiating pharmacotherapy as an adjunct to lifestyle intervention in patients who meet BMI thresholds, which strengthens the clinical rationale for PA letters. [6]

Medicare and Medicaid

Medicare Part D plans are prohibited by federal law from covering drugs approved solely for weight loss (Social Security Act Section 1860D-2(e)(2)), which historically excluded Saxenda. The Treat and Reduce Obesity Act, pending in Congress as of early 2026, would remove that exclusion but has not yet passed. [7] Medicaid coverage varies by state; fewer than 15 states covered anti-obesity medications for all Medicaid enrollees as of a 2024 KFF analysis. [8]

Step Therapy and Formulary Placement

Even when a plan covers Saxenda, it may require "step therapy," meaning patients must try and fail on a lower-tier agent first (often orlistat or phentermine/topiramate). Documenting the failure, contraindication, or intolerance to a step-therapy agent is the fastest route to a Saxenda approval.

The NovoCare Patient Assistance Program

For patients who are uninsured or whose income falls below the program threshold, Novo Nordisk operates NovoCare, a patient assistance program (PAP) that provides Saxenda at no cost or reduced cost.

Eligibility Requirements

As of 2026, NovoCare requires:

• No insurance coverage for Saxenda (or coverage that results in an unaffordable copay after the My$avings Card is applied)
• Annual household income at or below 400% of the federal poverty level (FPL), though Novo Nordisk adjusts this threshold periodically
• U.S. Residency and a valid prescription from a licensed U.S. Prescriber

The Health Resources and Services Administration's definition of federal poverty guidelines is the reference standard NovoCare uses to verify income. [9]

How to Apply

Patients or providers can initiate a NovoCare application at 1-866-310-7549 or through the Novo Nordisk website. The application requires:

• Proof of income (tax return, pay stubs, or SSI/SSDI award letter)
• A signed prescription
• Completed program enrollment form

Processing time is typically 2 to 4 weeks. Approved patients receive Saxenda shipped directly to the prescribing provider's office or, in some states, directly to the patient's home. The supply period is usually 90 days, after which patients re-certify eligibility.

Clinical Effectiveness: What the Evidence Shows

Understanding Saxenda's cost is inseparable from understanding its clinical value. The drug's PA approval and insurance coverage depend partly on demonstrating to payers that GLP-1 therapy produces meaningful outcomes.

The SCALE Obesity and Prediabetes Trial

The landmark SCALE Obesity and Prediabetes trial (N=3,731) tested liraglutide 3 mg against placebo in adults with obesity or overweight plus dyslipidemia or hypertension over 56 weeks. Liraglutide 3 mg produced a mean weight loss of 8.4 kg (8.0% of body weight) versus 2.8 kg (2.6%) for placebo. [10] The study was published in the New England Journal of Medicine in 2015 and remains the primary efficacy reference insurers cite in coverage decisions. [10]

SCALE Diabetes

In patients with type 2 diabetes, the SCALE Diabetes trial (N=846) found liraglutide 3 mg reduced body weight by 6.0% versus 2.0% for placebo over 56 weeks, with a statistically significant reduction in HbA1c of 1.3 percentage points (P<0.001). [11] This dual benefit of glycemic and weight improvement strengthens the clinical argument for coverage in diabetic patients.

Adolescent Data

The SCALE Teens trial (N=251) tested liraglutide 3 mg in adolescents aged 12 to 17 with obesity over 56 weeks. Participants receiving liraglutide had a mean BMI standard deviation score reduction of 0.22 versus an increase of 0.22 in the placebo group. [12] The FDA's June 2020 labeling update for the adolescent indication was based on these data. [5]

Cardiovascular Outcomes

The LEADER trial (N=9,340) evaluated liraglutide 1.8 mg (the diabetes dose, not 3 mg) and found a 13% relative risk reduction in major adverse cardiovascular events versus placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority). [13] While LEADER used the lower diabetes dose, prescribers and payers cite it when making benefit-risk arguments for the obesity dose, given the shared mechanism of action. A dedicated CVOT for liraglutide 3 mg has not been completed as of this writing.

Comparing Saxenda to Wegovy on Cost and Coverage

Semaglutide 2.4 mg (Wegovy, Novo Nordisk) is the other major injectable GLP-1 approved for weight management. The two drugs share the same manufacturer and a broadly similar access pathway, but differ in clinical profile and current insurance field.

Weight Loss Outcomes

The STEP-1 trial (N=1,961) found semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight at 68 weeks versus 2.4% for placebo. [14] That is roughly double the weight loss seen with liraglutide 3 mg in SCALE. Insurers increasingly use this outcome differential when deciding formulary placement, sometimes placing Wegovy on a preferred tier over Saxenda.

Cost Comparison

Wegovy's list price is approximately $1,349 to $1,650 per month depending on dose and pharmacy, comparable to Saxenda. Novo Nordisk operates a similar copay card for Wegovy. The practical difference for patients often comes down to which drug their specific commercial plan covers and at what tier, not list price.

Why Some Patients Still Choose Saxenda

Saxenda's daily injection schedule can be an advantage for patients who prefer smaller, more frequent doses during the titration phase. Saxenda also has a longer published safety record (approved 2014 versus Wegovy's 2021 approval) and more data in adolescents. The Endocrine Society's clinical practice guideline on obesity pharmacotherapy notes that drug selection should account for comorbidities, tolerability history, and individual patient preference rather than weight loss magnitude alone. [6]

Practical Steps to Minimize Your Saxenda Cost

The following decision framework reflects the HealthRX clinical access protocol for liraglutide 3 mg and is designed to be worked through in order before a prescription is sent to pharmacy.

Step 1: Confirm insurance coverage before writing the prescription. Call the member services number on the back of the patient's insurance card and ask specifically whether liraglutide 3 mg (Saxenda, NDC prefix 00169) is on formulary and what tier it occupies. Ask whether a PA is required and what the step therapy requirements are.

Step 2: Submit a thorough prior authorization at the first attempt. A complete PA at submission reduces denial rates significantly. Include BMI documentation, comorbidity records, and a 3-to-6-month diet and exercise history. The CDC's Adult BMI calculator methodology is an acceptable reference for BMI documentation in PA letters. [15]

Step 3: Apply for the My$avings Card before the first fill. Activation takes less than 10 minutes online. The card number can be given to the pharmacy immediately and used starting with the first prescription.

Step 4: If denied, file an appeal citing SCALE trial data. Insurance appeals citing peer-reviewed clinical evidence succeed at a meaningfully higher rate than appeals without citations. Reference SCALE Obesity (NEJM 2015) and the Endocrine Society guideline recommendation directly in the appeal letter.

Step 5: If commercially uninsured, apply to NovoCare simultaneously with Step 2. NovoCare processing takes 2 to 4 weeks, so applying early prevents a coverage gap.

Step 6: If NovoCare income thresholds are not met and coverage is denied, discuss alternative anti-obesity pharmacotherapy. Phentermine/topiramate ER and naltrexone/bupropion SR carry substantially lower list prices ($60 to $200 per month) and may be covered by plans that exclude GLP-1 agents. The 2023 American Heart Association statement on obesity pharmacotherapy provides a comparative review of approved agents. [16]

Monitoring Requirements That Affect Ongoing Coverage

Insurers increasingly require documented clinical response to continue coverage beyond the initial authorization period. Saxenda's label sets a specific benchmark: if a patient has not lost at least 4% of baseline body weight by week 16, the drug should be discontinued. [5]

Tracking Weight at 8 and 16 Weeks

HealthRX providers document weight at every visit and flag patients approaching the 16-week threshold who have not reached 4% loss. Early recognition allows a shared decision-making conversation about titration optimization, dietary adherence, or transition to an alternative agent before the insurer's coverage review.

Side Effect Documentation

Nausea, vomiting, and injection-site reactions are the most common adverse effects with liraglutide 3 mg. The SCALE trials reported nausea in approximately 39% of participants. [10] Documenting side effect management (dose titration, dietary modification, antiemetics) in the chart supports continued medical necessity arguments and helps differentiate medically driven non-response from adherence issues.

Thyroid Monitoring

Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent data. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome are contraindicated. Calcitonin monitoring is not routinely recommended by the FDA label but should be considered in patients with thyroid nodules or abnormal ultrasound findings. [5] The National Cancer Institute's overview of medullary thyroid carcinoma, available through the NIH Bookshelf, is a useful clinical reference for screening questions. [17]